Systemic inflammatory response syndrome (SIRS) refers to the body’s overwhelming response to a stressor. It can be caused by an infection, trauma, or a worsening health condition, among others. Systemic inflammatory response syndrome requires immediate treatment in a hospital. The growing incidence of stressors such as sepsis, trauma, or pancreatitis coupled with the expanding aging population and increasing surgical interventions are fueling the demand for effective treatments. Moreover, the rising advancements in biotechnology, including CRISPR, mRNA technology, and advanced biologics, are encouraging investment in the pipeline.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic inflammatory response syndrome.
Systemic Inflammatory Response Syndrome therapeutics include antibiotics or antiviral agents if SIRS is triggered by bacterial or viral infections, respectively. Systemic inflammatory response syndrome emerging drugs like siRNA or mRNA-based therapies, cytokine inhibitors, and stem cell therapies are expected to diversify therapeutic options and augment treatment market growth. Further, the increasing investment in clinical trials to evaluate novel therapies along with the rising focus on personalized medicine are anticipated to support the drug pipeline expansion in the coming years.
Owing to the nonspecific nature of the definition of systemic inflammatory response syndrome, the exact incidence of the condition is unknown but is expected to be very high.
Drug: MultiStem®
Healios K.K. is conducting a Phase II study aimed at examining the efficacy and safety of the investigational injectable drug MultiStem® to treat trauma induced multiple organ failure/systemic inflammatory response syndrome. The clinical trial has enrolled about 156 subjects and is expected to be completed by December 2025.
This product will be delivered within 3-5 business days.
Report Coverage
The Systemic Inflammatory Response Syndrome Drug Pipeline Insight Report by the publisher gives comprehensive insights into systemic inflammatory response syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic inflammatory response syndrome. The systemic inflammatory response syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic inflammatory response syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with systemic inflammatory response syndrome treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic inflammatory response syndrome.
Systemic Inflammatory Response Syndrome Drug Pipeline Outlook
Systemic inflammatory response syndrome (SIRS) is an inflammatory state caused by the body's reaction to an infectious or noninfectious agent. The exaggerated defense response of the body can lead to organ failure and even death. If SIRS occurs due to a known infection, it's called sepsis. Common symptoms include edema in the affected parts of the body, intense fatigue and/or pain, fast heart rate, chills, or skin rash, among others.Systemic Inflammatory Response Syndrome therapeutics include antibiotics or antiviral agents if SIRS is triggered by bacterial or viral infections, respectively. Systemic inflammatory response syndrome emerging drugs like siRNA or mRNA-based therapies, cytokine inhibitors, and stem cell therapies are expected to diversify therapeutic options and augment treatment market growth. Further, the increasing investment in clinical trials to evaluate novel therapies along with the rising focus on personalized medicine are anticipated to support the drug pipeline expansion in the coming years.
Systemic Inflammatory Response Syndrome Epidemiology
Systemic inflammatory response syndrome is a life-threatening condition characterized by inflammation throughout the body. Prompt treatment can help in the complete recovery of the patient. However, nearly 7% of SIRS patients die from the syndrome, with mortality rates for sepsis estimated to be 28% for septic shock, 9.2% for severe sepsis, and 1.3% for sepsis.Owing to the nonspecific nature of the definition of systemic inflammatory response syndrome, the exact incidence of the condition is unknown but is expected to be very high.
Systemic Inflammatory Response Syndrome - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of systemic inflammatory response syndrome drug candidates based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Biologics
- Peptides
- RNA-Based Therapies
- Cell-Based Therapies
- Nanoparticle-Based Drugs
- Synthetic Polymers
By Route of Administration
- Oral
- Parenteral
- Others
Systemic Inflammatory Response Syndrome - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of systemic inflammatory response syndrome drugs undergoing clinical development.Systemic Inflammatory Response Syndrome - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under systemic inflammatory response syndrome pipeline analysis include small molecules, biologics, peptides, RNA-based therapies, cell-based therapies, nanoparticle-based drugs, and synthetic polymers. The systemic inflammatory response syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic inflammatory response syndrome.Systemic Inflammatory Response Syndrome Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the systemic inflammatory response syndrome drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed systemic inflammatory response syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in systemic inflammatory response syndrome clinical trials:- Healios K.K.
- Grand Medical Pty Ltd.
- Vivacelle Bio
- Op-T LLC
- Novartis Pharmaceuticals
- Mundipharma Research Limited
Systemic Inflammatory Response Syndrome - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Drug: VBI-S
Sponsored by Vivacelle Bio, the objective of this randomized clinical trial is to investigate the efficacy and safety of the systemic inflammatory response syndrome drug candidate VBI-S in patients experiencing hypovolemia with septic shock. The study is under Phase III clinical development and has an estimated 46 participants.Drug: MultiStem®
Healios K.K. is conducting a Phase II study aimed at examining the efficacy and safety of the investigational injectable drug MultiStem® to treat trauma induced multiple organ failure/systemic inflammatory response syndrome. The clinical trial has enrolled about 156 subjects and is expected to be completed by December 2025.
Reasons To Buy This Report
The Systemic Inflammatory Response Syndrome Drug Report provides a strategic overview of the latest and future landscape of treatments for systemic inflammatory response syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within systemic inflammatory response syndrome pipeline insights.Key Questions Answered in the Systemic Inflammatory Response Syndrome - Pipeline Insight Report
- What is the current landscape of systemic inflammatory response syndrome disease pipeline drugs?
- Which companies/institutions are developing systemic inflammatory response syndrome disease emerging drugs?
- How many phase II drugs are currently present in systemic inflammatory response syndrome disease pipeline drugs?
- Which company is leading the systemic inflammatory response syndrome disease pipeline development activities?
- What is the current systemic inflammatory response syndrome disease therapeutic assessment?
- What are the opportunities and challenges present in the systemic inflammatory response syndrome disease drug pipeline landscape?
- What is the efficacy and safety profile of systemic inflammatory response syndrome disease pipeline drugs?
- Which companies/institutions are involved in systemic inflammatory response syndrome disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in systemic inflammatory response syndrome disease?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Systemic Inflammatory Response Syndrome
4 Patient Profile: Systemic Inflammatory Response Syndrome
5 Systemic Inflammatory Response Syndrome: Epidemiology Snapshot
6 Systemic Inflammatory Response Syndrome: Market Dynamics
7 Systemic Inflammatory Response Syndrome: Key Facts Covered
8 Systemic Inflammatory Response Syndrome, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Systemic Inflammatory Response Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Systemic Inflammatory Response Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Systemic Inflammatory Response Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Systemic Inflammatory Response Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Systemic Inflammatory Response Syndrome, Key Drug Pipeline Companies
